Form 4: Aprea Therapeutics Director Michael Grissinger Reports Acquisition of Shares and Stock Options

Director Michael Grissinger reports acquisition of restricted stock units and stock options in Aprea Therapeutics.

Summary

• On June 20, 2024, Michael Grissinger, a director of Aprea Therapeutics, acquired 1,045 shares of common stock and 4,185 stock options.
• The shares were granted as restricted stock units and will vest on June 20, 2025, contingent upon continued service on the board.
• The stock options, with an exercise price of $4.07, also vest on June 20, 2025, subject to continued board service.
• Following the transaction, Grissinger beneficially owns 1,844 shares of common stock and 4,185 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a common practice and indicates alignment of interests between the director and the company's shareholders. There are no immediate negative implications.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future.
• The vesting conditions tied to continued service align the director's interests with the long-term success of the company.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the director's continued service, suggesting an expectation of ongoing involvement and commitment to the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the beneficial ownership of Aprea Therapeutics' securities by a director.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates